v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents $ 43,163 $ 47,920
Short-term marketable securities (amortized cost of $154,672 and $174,186, respectively) 154,710 174,374
Accounts receivable, net 44,285 41,731
Inventory, net 8,403 8,440
Prepaid expenses and other current assets 11,295 11,287
Total current assets 261,856 283,752
Long-term assets    
Property and equipment, net 41,055 48,616
Operating lease right-of-use assets 43,338 45,767
Long-term marketable securities (amortized cost of $24,065 and $33,682, respectively) 24,100 33,660
Restricted cash 2,720 2,897
Intangible assets, net 2,583 3,425
Goodwill 118,972 118,972
Other assets 2,013 2,287
Total assets 496,637 539,376
Current liabilities    
Accounts payable 6,908 7,265
Accrued liabilities 7,205 8,157
Accrued compensation and benefits 9,700 15,838
Current portion of operating lease liabilities 9,957 10,239
Current portion of deferred revenue 55,301 55,689
Current portion of revenue interest liability, net 3,070 865
Total current liabilities 92,141 98,053
Long-term liabilities    
Operating lease liabilities, less current portion 74,413 79,148
Deferred revenue, less current portion 20,032 27,256
Revenue interest liability, net, less current portion 130,495 132,414
Other long-term liabilities 20 20
Total liabilities 317,101 336,891
Commitments and contingencies (Note 9)
Shareholders’ equity    
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2025 and December 31, 2024; 152,234,772 and 147,773,744 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 15 14
Additional paid-in capital 1,538,919 1,506,353
Accumulated other comprehensive gain 73 166
Accumulated deficit (1,359,290) (1,303,824)
Total Adaptive Biotechnologies Corporation shareholders’ equity 179,717 202,709
Noncontrolling interest (181) (224)
Total shareholders’ equity 179,536 202,485
Total liabilities and shareholders’ equity $ 496,637 $ 539,376